Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYCN
- Development stage
- Preclinical
- Lead developer
- Asahikawa Medical University
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
MYCN is a proto-oncogene being investigated as a therapeutic target and gene therapy candidate for cardiac regeneration. In the context of myocardial infarction (MI), MYCN is delivered via cardiomyocyte-specific adeno-associated viral (AAV) vectors to induce cell cycle activity in mature cardiomyocytes, which typically have limited regenerative capacity. Preclinical studies in mature mice have demonstrated that overexpression of the Mycn isoform promotes cardiomyocyte mitosis, angiogenesis, and fibroblast activation. This therapeutic approach has shown potential in protecting cardiac function by preventing the significant decline in left ventricular ejection fraction (LVEF) following myocardial injury.
- Other names
- N-mycN-myc proto-oncogene proteinNMYC
02
Targets
MYCN (N-myc proto-oncogene protein)
Beyond the preview
Go deeper on MYCN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYCN.